Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05610189 · ClinicalTrials.gov registry record · Phase 1
Multiple-dose Trial to Determine the Clinical Bioequivalence Between Tavapadon Tablets in Participants With Parkinson's Disease
A Phase 1 study of Parkinson Disease, sponsored by Cerevel Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
- 6
- Study locations
NCT05610189: Completed Phase 1 study of Parkinson Disease, sponsored by Cerevel Therapeutics.
NCT05610189 is a Phase 1 study of Parkinson Disease that has completed, run by Cerevel Therapeutics. The registered enrollment target is 25 participants, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (100% lower). The trial reports 6 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05610189, a Phase 1 study of Parkinson Disease, has completed, sponsored by Cerevel Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
- 6
- Study locations
Study Summary
The primary purpose of the study is to evaluate the bioequivalence (BE) of tavapadon 15 milligram (mg) tablet to 3x5 mg tablets in participants with Parkinson's disease.
Conditions Studied
Interventions
- DRUG Tavapadon
Study Locations (6)
Florida
- Hollywood, Florida - Hollywood
- Orlando, Florida - Orlando
- South Miami, Florida - South Miami
California
- Los Alamitos, California - Los Alamitos
Georgia
- Decatur, Georgia - Decatur
Michigan
- Farmington Hills, Michigan - Farmington Hills
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2022-12-15 |
| Est. Completion | 2023-12-17 |
| Phase | Phase 1 |
What the finished NCT05610189 record still lists
NCT05610189 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Parkinson Disease appearing as the primary indexed condition, and to 1 intervention - of which Tavapadon is the first listed.
NCT05610189 lists 6 locations in 4 states (Florida, California, Georgia).
Frequently Asked Questions
What is clinical trial NCT05610189 about?
NCT05610189 is a clinical study titled "Multiple-dose Trial to Determine the Clinical Bioequivalence Between Tavapadon Tablets in Participants With Parkinson's Disease". The primary purpose of the study is to evaluate the bioequivalence (BE) of tavapadon 15 milligram (mg) tablet to 3x5 mg tablets in participants with Parkinson's disease.
What is the current status of trial NCT05610189?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2022-12-15. Estimated completion is 2023-12-17.
What conditions does trial NCT05610189 study?
This clinical trial studies the following conditions: Parkinson Disease.
What interventions are being tested in trial NCT05610189?
The interventions under investigation include: Tavapadon (DRUG).
Who is sponsoring clinical trial NCT05610189?
This trial is sponsored by Cerevel Therapeutics, which has 21 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05610189 being conducted?
This trial has 6 study locations across California, Florida, Georgia, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05610189's enrollment target sits among peer trials
25 225th of 297 higher than 67 of 297 other Parkinson Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinson Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease
RECRUITING · Phase 1
-
Treating Parkinson's Disease Through Transplantation of Autologous Stem Cell-Derived Dopaminergic Neurons
RECRUITING · Phase 1
-
First-in-Human Single and Multiple Dose of HL-400
RECRUITING · Phase 1
-
Phase 2 Trial of Tributyrin in People With Parkinson's Disease and Cognitive Impairments
RECRUITING · Phase 1
-
[18F]F-DOPA Imaging in Patients With Autonomic Failure
RECRUITING · Phase 1
-
A Study to Assess the Safety of BMS-984923 Compared to Placebo, in People With Parkinson's
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI